SRPT
Sarepta Therapeutics Inc (SRPT)
Healthcare • NASDAQ • $19.96-4.06%
- Symbol
- SRPT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $19.96
- Daily Change
- -4.06%
- Market Cap
- $2.11B
- Trailing P/E
- 57.01
- Forward P/E
- 6.82
- 52W High
- $44.14
- 52W Low
- $10.42
- Analyst Target
- $22.77
- Dividend Yield
- N/A
- Beta
- 0.26
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 …
Company websiteResearch SRPT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.